GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,630.00
Bid: 1,630.00
Ask: 1,630.50
Change: -20.50 (-1.24%)
Spread: 0.50 (0.031%)
Open: 1,650.50
High: 1,658.50
Low: 1,628.50
Prev. Close: 1,650.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Down As Clinton Remarks Hit Pharma Sector

Thu, 25th Aug 2016 11:00

LONDON (Alliance News) - Pharmaceutical stocks dragged the FTSE 100 lower midday Thursday, after the sector was hit by comments made by presidential nominee Hillary Clinton, who raised concerns about the price increase of an allergy product by US pharmaceutical company Mylan.

The price of the company's EpiPen product has risen by 480% since the company acquired it in 2007, moving from USD100 for a 2-pack in 2007 to its current cost of around USD600.

"That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," said Clinton in a statement published on her Facebook profile. "It's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them."

Mike van Dulken, head of research at Accendo Markets, said Clinton's comments will cause concern for healthcare groups and their investors everywhere.

"As always, the industry remains between a rock and a hard place, treading the fine line between balancing the costs of clinical success (and failure) with the economic laws of supply and demand, all the while trying (often in vain) to satisfy demanding stakeholders without appearing to view the sick as merely a commercial opportunity," van Dulken said.

Hikma Pharmaceuticals was down 3.6%, Shire down 4.4%, AstraZeneca down 1.8%, and GlaxoSmithKline down 0.7%.

The FTSE 100 was down 0.3%, or 18.32 points, at 6,817.46. The FTSE 250 was down 0.8% at 17,869.99 and the AIM All-Share was down 0.5% at 788.35.

In Europe, the French CAC 40 was down 0.7% and the German DAX 30 was down 0.9%

Futures indicated a lower open for Wall Street, with the DJIA, S&P 500, and Nasdaq 100 all pointed down 0.1%.

Elsewhere on the London market, CRH was the best performer in the blue-chip index, up 3.4%. The Irish building materials company said its profit came in six times higher than a year earlier in its first half, reflecting continued positive momentum in the Americas and the inclusion of acquisitions made in the second half of 2015.

CRH said trading conditions in the first half in Europe reflected the modest impact of early-stage economic recovery.

In the Americas, the company said it expects the positive momentum seen in construction markets during the first half of the year to continue into the second, while in Asia the positive demand backdrop experienced in the Philippines looks set to continue for the rest of the year.

ITV said it has withdrawn its proposal to acquire Entertainment One, after the television and film producer rejected the bid earlier this month.

ITV made an offer for Entertainment One at 236.00 pence per share, valuing it at around GBP1.03 billion, in early August, but this bid was rebuffed by Entertainment One's board as it said it "fundamentally undervalues" the business.

ITV said Thursday that it has a "clear view of the value" of Entertainment One, and it "appears this value is different to the level at which the board of eOne would currently engage in a more formal process."

The broadcaster said it has a "clear strategy to build a stronger, more diversified international business and will continue its disciplined approach to evaluating its healthy pipeline of potential investment opportunities."

ITV traded up 1.5%, while Entertainment One was the biggest faller in the FTSE 250 index, down 12% to 220.21p.

Infrastructure investor John Laing Group said its net asset value rose in the first half of 2016 and maintained its full year guidance for investment commitments.

The company's net asset value per share also rose to 263.00 pence at the end of its first half from 242.00p at the end of December and 224.00p a year earlier.

"These results demonstrate that our business model is delivering consistent results, and has the ability to cope with today's changing macro-economic environment, including the impact of Brexit," said Chief Executive Olivier Brousse.

The stock was one of the best FTSE 250 performers, up 5.6%.

Playtech was up 4.3% after the gaming technology company reported growth in revenue in the first half and declared a special dividend, but said its profit dipped due to higher finance costs hit by the depreciation of sterling.

Playtech added it was "cognisant" of the need for an efficient balance sheet and said its currently high cash balance is complemented by cash from operations.

It added it is able to return cash to shareholders without impact in its outlook on making more acquisitions. As such, it will pay an interim dividend of 11.0 euro cents per share, up 15% from the previous year, and declared a special dividend of a further 46.0 cents per share.

Still ahead in the economic calendar, US initial and continuing jobless claims are at 1330 BST, alongside durable goods data. Markit's US services and composite PMI readings are at 1445 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.